Date: Wednesday, June 12, 2019
Time: 12:00PM EST
Biopharmaceutical products in development continue to increase in complexity. These include numerous multi-specific antibody platforms, proteins that require cleavage, or other additional post-translational modifications not typically performed by CHO cells, as well as unique protein fusions and various protein conjugates. Many of these types of molecules require multiple proteins to be expressed at differing ratios to get the correct biopharmaceutical produced at maximum titer and quality.
New cell line development methodologies as well as new instrumentation are enabling these complex programs to be performed more efficiently. In this webinar, we outline two successful case studies taking complex biopharmaceuticals to clinical production and how the Beacon® platform for clonal cell line selection and the use of ambr® bioreactor systems will help improve development timelines and the quality of the cell lines for these types of molecules.
Key Learning Objectives:
- Understand the key challenges associated with developing complex and non-traditional antibody-based biologics
- Learn about new technologies that improve the robustness of cell line and process development platforms
- Review data that compares expression levels of complex biologics utilizing different development methods
- Uncover other benefits, besides increased titer, that can be achieved by utilizing these strategies
Gregory Bleck, PHD
Global Head of R&D, Biologics
Tanner Nevill, PhD
VP, Product Applications